Loading...
XSHG
605116
, Last price  
Name

Aurisco Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:605116 chart
P/E
—
P/S
—
EPS
1.11
Vol. 1Y
—
Shs. 5Y
1.75%
Rev. 5Y
18.66%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.70b
+15.03%
590,421,818544,401,751575,412,151581,632,760721,440,229803,362,6671,008,076,4721,262,530,8811,475,741,0331,697,477,562
Net income
449m
+26.61%
86,703,65144,720,786136,829,876186,130,281157,227,224168,713,892210,964,635289,419,393354,792,034449,210,068
CFO
421m
+26.80%
188,299,196117,907,715109,768,700179,903,617214,481,140201,570,616166,408,435385,605,549332,405,825421,496,354
Dividend
Jun 15, 20260.34 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
IPO date
Sep 21, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT